We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Affibody AB and GE Healthcare in Molecular Collaboration

By MedImaging staff writers
Posted on 28 Jun 2006
Print article
Affibody AB (Stockholm, Sweden) has entered a research agreement with GE Healthcare (Chalfont Sr. Giles, UK), a division of the General Electric Co.. Under the agreement, Affibody will provide Affibody molecules for three disease targets as defined by GE Healthcare.

Affibody molecules, with their favorable biodistribution, high target specificity, and acceptability to protein-engineering approaches, are considered suitable candidates for targeted in vivo imaging applications. The goal is to allow early diagnosis of disease and thereby allowing clinicians to optimize the therapy on a customized basis. Under the agreement, GE Healthcare has the exclusive option to take any licenses required for developing and marketing imaging agents resulting from this collaboration. Affibody retains all rights for use of the selected Affibody molecules outside the scope of in vivo diagnostic and medical imaging.

Dr. Ulf Boberg, chief executive officer, Affibody, commented, "We are delighted to announce an agreement with GE Healthcare, regarded as a leader in the rapidly expanding field of molecular imaging. This agreement broadens the current uses of Affibody molecules in medicine, and demonstrates the increasing interest in the use of molecular imaging agents to monitor disease.”

Affibody uses innovative protein engineering technologies for the development of the affinity ligand, Affibody molecules. These small, robust protein molecules can be designed to bind to a number of target proteins, are easily produced, and have a high stability in a broad range of conditions. They appear well-suited for molecular imaging, and when combined with a cytotoxic payload, could potentially be utilized for targeted therapy.

Affibody also develops Affibody molecules for various biotechnology applications in a number of commercial collaborations. Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute (Stockholm, Sweden).



Related Links:
Affibody
GE Healthcare
New
Gold Member
X-Ray QA Meter
T3 AD Pro
New
Mini C-arm Imaging System
Fluoroscan InSight FD
NMUS & MSK Ultrasound
InVisus Pro
Imaging Table
CFPM201

Print article
Radcal

Channels

Radiography

view channel
Image: The new X-ray detector produces a high-quality radiograph (Photo courtesy of ACS Central Science 2024, DOI: https://doi.org/10.1021/acscentsci.4c01296)

Highly Sensitive, Foldable Detector to Make X-Rays Safer

X-rays are widely used in diagnostic testing and industrial monitoring, from dental checkups to airport luggage scans. However, these high-energy rays emit ionizing radiation, which can pose risks after... Read more

MRI

view channel
Image: The scans revealed a new dimension of brain network organization in humans (Photo courtesy of Georgia State University/TReNDS Center Research)

New Approach Identifies Signatures of Chronic Brain Disorders Using fMRI Scans

Traditional studies of brain function, often using fMRI scans to detect brain activity patterns, have shown promise in identifying changes in individuals with chronic brain disorders like schizophrenia.... Read more

Nuclear Medicine

view channel
Image: Example of AI analysis of PET/CT images (Photo courtesy of Academic Radiology; DOI: 10.1016/j.acra.2024.08.043)

AI Analysis of PET/CT Images Predicts Side Effects of Immunotherapy in Lung Cancer

Immunotherapy has significantly advanced the treatment of primary lung cancer, but it can sometimes lead to a severe side effect known as interstitial lung disease. This condition is characterized by lung... Read more

General/Advanced Imaging

view channel
Image: Cleerly offers an AI-enabled CCTA solution for personalized, precise and measurable assessment of plaque, stenosis and ischemia (Photo courtesy of Cleerly)

AI-Enabled Plaque Assessments Help Cardiologists Identify High-Risk CAD Patients

Groundbreaking research has shown that a non-invasive, artificial intelligence (AI)-based analysis of cardiac computed tomography (CT) can predict severe heart-related events in patients exhibiting symptoms... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.